Rapport Therapeutics Reports Sustained Seizure Reduction in Phase 2a RAP-219 Study: Implications for Investors

Key Highlights

• Significant sustained efficacy: RAP-219 demonstrated a 90% median reduction in clinical seizures over baseline during weeks 9-12 of the follow-up period and a 59% median reduction in weeks 13-16.
• Durable pharmacokinetics: New data show RAP-219 has a half-life of ~22 days, supporting prolonged therapeutic exposure after dosing ends.
• Safety profile: RAP-219 was generally well tolerated, with only mild treatment-related adverse events reported and no serious adverse events deemed related to the drug.
• Imminent pivotal trials: Two Phase 3 trials in focal onset seizures (FOS) are expected to begin in Q2 2026, with other key studies in bipolar mania and generalized tonic-clonic seizures scheduled for 2027.
• Novel mechanism of action: RAP-219 is a potential first-in-class, TARPγ8-specific AMPA receptor negative allosteric modulator, offering targeted therapy with potentially fewer side effects.
• Pipeline expansion: Development of a long-acting injectable (LAI) formulation of RAP-219 continues, with Phase 1 PK results expected in 2027.

Detailed Study Results

Rapport Therapeutics (Nasdaq: RAPP) has released robust follow-up data from its Phase 2a trial of RAP-219 in drug-resistant focal onset seizures (FOS), presented at the 2026 American Academy of Neurology Annual Meeting in Chicago.
Following 8 weeks of RAP-219 treatment, patients entered an 8-week follow-up period with no further dosing. During this follow-up, RAP-219 maintained therapeutic plasma levels due to its extended half-life, ensuring sustained efficacy.

Clinical Efficacy Results

Median percent reductions and seizure freedom rates remained notable over extended periods:

• Weeks 1-12: 71% reduction in LEs, 75% reduction in clinical seizures, 20% seizure freedom rate.
• Weeks 1-16: 69% reduction in LEs, 68% reduction in clinical seizures, 12% seizure freedom rate.
• For the 8-week treatment period, 24% achieved complete seizure freedom.

Pharmacokinetics and Mechanism

Population PK modeling from Phase 1 and 2 trials now estimates RAP-219’s half-life at approximately 22 days, a significant increase from the previously reported 14 days. This supports sustained therapeutic exposures and clinical effects after treatment ends, with receptor occupancy remaining above 60% throughout the follow-up.

RAP-219 acts as a TARPγ8-specific AMPA receptor negative allosteric modulator, offering selectivity for brain regions implicated in seizures (hippocampus and neocortex) with reduced expression in areas linked to side effects. This precision may differentiate RAP-219 from other CNS drugs.

Safety and Tolerability

The drug was well tolerated in the follow-up period. Only two patients reported mild, treatment-related adverse events. Three patients experienced serious adverse events, none of which were considered related to RAP-219.

Upcoming Milestones and Pipeline Expansion

• Phase 3 Trials: FOCUS 1 and FOCUS 2 pivotal trials in FOS are slated to start in Q2 2026.
• Long-term Safety: An ongoing open-label extension (OLE) study will provide additional safety data, with initial results expected in H2 2026.
• Broader Indications: Phase 2 trial in bipolar mania (topline data H1 2027), Phase 3 trial in primary generalized tonic-clonic seizures (to begin H1 2027).
• LAI Formulation: Phase 1 PK results for the long-acting injectable version anticipated in 2027.

Implications for Shareholders

• Price Sensitive Information: The demonstration of sustained clinical efficacy, including 90% median reduction in seizures in weeks 9-12 after treatment cessation, and the extension of RAP-219’s half-life, are positive surprises that may drive investor optimism. These results suggest robust long-term disease control and support for RAP-219’s differentiated clinical and commercial potential.
• Upcoming Value Drivers: Imminent initiation of two pivotal Phase 3 trials and advancement into additional indications (bipolar mania, generalized tonic-clonic seizures) represent major catalysts for the stock.
• Pipeline-in-a-Product Potential: With a novel mechanism, favorable safety profile, and extended applicability across neurological and psychiatric disorders, RAP-219 could become a best-in-class therapy, further supporting valuation upside.
• Risk Factors: Investors should weigh potential regulatory, development, and competitive risks, as well as the need for additional capital as the pipeline advances.

Management Commentary

“Clinical outcomes improved further during the first four weeks after dosing ended, highlighted by a 90% reduction in clinical seizures, and consistent with the observed PK. These data demonstrate RAP-219’s treatment effect in focal onset seizures out to 16 weeks of therapeutic drug exposure and show a consistent dose-exposure-clinical outcome relationship that provides us confidence in the doses we’re advancing in Phase 3 trials.”
— William Motley, M.D., D. Phil., RAP-219 Program Leader

“We believe these follow-up period results underscore the sustained activity of RAP-219 beyond the 8-week treatment period. Together with the treatment period data, these findings further support our view that RAP-219 has the potential to become a differentiated, best-in-class therapy and an important new treatment option for patients with focal onset seizures.”
— Jeffrey Sevigny, M.D., Chief Medical Officer

Conclusion

The latest Phase 2a follow-up data for RAP-219 from Rapport Therapeutics demonstrate unprecedented durability and magnitude of seizure reduction, which, combined with a favorable safety and PK profile, substantially de-risks the ongoing development program. The imminent start of Phase 3 registration trials, along with a growing pipeline in high-value CNS indications, positions Rapport as a key stock to watch in the neuroscience space.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should review all available information, including company filings and risk factors, and consult their own financial advisors before making investment decisions. The author and publisher accept no liability for actions taken based on this report.

View Rapport Therapeutics, Inc. Historical chart here